Skip to main content
Premium Trial:

Request an Annual Quote

10X Genomics Partners With BioLegend, Immudex on Barcoding Tech Applications

NEW YORK (GenomeWeb) – 10X Genomics said today it is partnering with BioLegend and Immudex to apply its barcoding technology to measuring gene and protein expression at the single-cell level.

10X and BioLegend will co-engineer BioLegend's TotalSeqB and TotalSeq C products to work with 10X's Chromium Single Cell Gene Expression Solution or its Single Cell Immune Profiling Solution and its Feature Barcoding Technology. 10X is partnering with Immudex to combine its barcoding technology with that company's Dextramer product, which will allow users to profile the binding of antigen-specific T cells while also analyzing their genetic content and cell surface markers.

Financial and other terms of the agreements were not disclosed.

"Such high resolution and complex information can be used to more deeply characterize highly heterogenous cellular populations and to further identify rare and important cells within those populations," BioLegend CEO Gene Lay said in a statement. "These insights can potentially lead to the identification of novel molecular therapeutic targets and can accelerate drug discovery in immune-oncology, autoimmunity, neurodegeneration, and other areas of human disease."

Immudex CSO Liselotte Brix added that combining her company's Dextramer technology with 10X Genomics' Chromium System will enable Immudex "to directly interrogate the TCR of the antigen-specific T Cells via MHC-peptide binding along with simultaneous analysis of expressed genes and cell surface phenotype for an entire sample at the single cell level."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.